Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia

Tavernier, 2007, Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial, Leukemia, 21, 1907, 10.1038/sj.leu.2404824

Fielding, 2007, Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study, Blood, 109, 944, 10.1182/blood-2006-05-018192

Gokbuget, 2016, International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia, Haematologica, 101, 1524, 10.3324/haematol.2016.144311

Gokbuget, 2012, Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation, Blood, 120, 2032, 10.1182/blood-2011-12-399287

Pulte, 2008, Trends in 5-and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990–2004, JNCI, 100, 1301, 10.1093/jnci/djn276

Teachey, 2013, Predicting relapse risk in childhood acute lymphoblastic leukaemia, Br J Haematol, 162, 606, 10.1111/bjh.12442

Maury, 2016, Rituximab in B-Lineage adult acute lymphoblastic leukemia, N Engl J Med, 375, 1044, 10.1056/NEJMoa1605085

Gokbuget, 2018, Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia, Blood, 131, 1522, 10.1182/blood-2017-08-798322

Kantarjian, 2017, Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia, N Engl J Med, 376, 836, 10.1056/NEJMoa1609783

Kantarjian, 2019, Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study, Cancer, 125, 2474, 10.1002/cncr.32116

Kantarjian, 2016, Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia, N Engl J Med, 375, 740, 10.1056/NEJMoa1509277

Richard-Carpentier, 2018, A phase II study of the hyper-CVAD regimen in sequential combination with blinatumomab as frontline therapy for adults with B-cell acute lymphoblastic leukemia (B-ALL), Hematology Am Soc Hematol Educ Program

Kantarjian, 2018, Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study, Lancet Oncol, 19, 240, 10.1016/S1470-2045(18)30011-1

Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3

Maude, 2018, Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia, N Engl J Med, 378, 439, 10.1056/NEJMoa1709866

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222

Park, 2018, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia, N Engl J Med, 378, 449, 10.1056/NEJMoa1709919

Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci Transl Med, 6, 10.1126/scitranslmed.3008226

Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J Clin Invest, 126, 2123, 10.1172/JCI85309

Gardner, 2017, Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood, 129, 3322, 10.1182/blood-2017-02-769208

Grupp, 2015, Durable remissions in children with Relapsed/Refractory ALL treated with t cells engineered with a CD19-Targeted chimeric antigen receptor (CTL019), Blood, 126, 10.1182/blood.V126.23.681.681

Jacoby, 2018, Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia, Am J Hematol, 93, 1485, 10.1002/ajh.25274

Kansagra, 2019, Bone Marrow Transplant

Ruella, 2016, Catch me if you can: leukemia escape after CD19-Directed t cell immunotherapies, Comput Struct Biotechnol J, 14, 357, 10.1016/j.csbj.2016.09.003

Sotillo, 2015, Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy, Cancer Discov, 5, 1282, 10.1158/2159-8290.CD-15-1020

Jacoby, 2016, CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity, Nat Commun, 7, 12320, 10.1038/ncomms12320

Li, 2018, Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB, Br J Haematol, 181, 360, 10.1111/bjh.15195

Pan, 2017, High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients, Leukemia, 31, 2587, 10.1038/leu.2017.145

Hu, 2017, Potent anti-leukemia activities of chimeric antigen receptor-modified t cells against CD19 in chinese patients with Relapsed/Refractory acute lymphocytic leukemia, Clin Cancer Res, 23, 3297, 10.1158/1078-0432.CCR-16-1799

Juweid, 2007, Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma, J Clin Oncol, 25, 571, 10.1200/JCO.2006.08.2305

Braig, 2017, Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking, Blood, 129, 100, 10.1182/blood-2016-05-718395

Kohnke, 2015, Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab, J Hematol Oncol, 8, 111, 10.1186/s13045-015-0213-6

Fry, 2018, CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy, Nat Med, 24, 20, 10.1038/nm.4441

Paul, 2019, Treatment of recurrent refractory pediatric Pre-B acute lymphoblastic leukemia using inotuzumab ozogamicin monotherapy resulting in CD22 antigen expression loss as a mechanism of therapy resistance, J Pediatr Hematol Oncol, 10.1097/MPH.0000000000001440

Shah, 2015, Characterization of CD22 expression in acute lymphoblastic leukemia, Pediatr Blood Cancer, 62, 964, 10.1002/pbc.25410

DeAngelo, 2017, Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study, Blood Adv, 1, 1167, 10.1182/bloodadvances.2016001925

Stein, 2019, Benefit-risk assessment of blinatumomab in the treatment of Relapsed/Refractory B-Cell precursor acute lymphoblastic leukemia, Drug Saf, 42, 587, 10.1007/s40264-018-0760-1

Fraietta, 2018, Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia, Nat Med, 24, 563, 10.1038/s41591-018-0010-1